Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Universal Ibogaine Inc ( (TSE:IBO) ) has issued an update.
Universal Ibogaine Inc. has announced its intention to file a Clinical Trial Application with Health Canada within 90 days to investigate ibogaine as a treatment for opioid use disorder. The company has secured a compliant supply of pharmaceutical-grade ibogaine, ensuring continuous availability for the planned trials. This move underscores UI’s commitment to advancing addiction therapies and positions it to conduct high-quality clinical studies. However, there is no guarantee that the application will be approved.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences company focused on transforming addiction treatment through medicalized ibogaine. The company aims to conduct a Canadian clinical trial targeting opioid use disorder and plans to expand its treatment protocol globally through future licensing agreements. Additionally, UI is developing a holistic addiction treatment protocol at its Kelburn Recovery Centre in Manitoba, which, combined with the ibogaine detox protocol, seeks to revolutionize addiction treatment.
Average Trading Volume: 312,542
Technical Sentiment Signal: Sell
Current Market Cap: C$4.12M
For a thorough assessment of IBO stock, go to TipRanks’ Stock Analysis page.